

In-vitro matured human macrophages express Alzheimer's β A4-amyloid precursor protein indicating synthesis in microglial cells

Joachim Bauer¹, Gerhard König², Sylvia Strauss³, Uwe Jonas¹, Ursula Ganter¹, Andreas Weidemann², Ursula Mönning², Colin L. Masters⁴, Benedikt Volk², Mathias Berger¹ and Konrad Beyreuther²

¹Psychiatrische Universitätsklinik, Universität Freiburg, Hauptstrasse 5, D-7800 Freiburg, Germany, ²Zentrum für Molekulare Biologie, Im Neuenheimer Feld 282, D-6900 Heidelberg, Germany, ³Abteilung Neuropathologie, Universität Freiburg, D-7800 Freiburg, Germany and ⁴Department of Pathology, University of Melbourne, Parkville, Victoria 3052, Australia

Received 22 February 1991; revised version received 8 March 1991

Microglia which are consistently associated with Alzheimer's disease (AD) senile plaques are part of the mononuclear phagocyte system. In-vitro matured human monocyte-derived macrophages feature many immunological characteristics of microglia. We found strong constitutive expression of Alzheimer's β A4-amyloid precursor protein (APP) in human mononuclear phagocytes after terminal in-vitro maturation from monocytes to macrophages. Amyloid has previously been found to be associated with microglia in AD brains, however, it remained unclear whether the material was synthesized in or had been phagocytosed by the cells. The findings presented here support the assumption that brain microglia may contribute to APP synthesis in AD brain.

Macrophage; Microglia; Amyloid precursor protein; Alzheimer's disease

1. INTRODUCTION

β -Amyloid or A4 protein, now termed β A4 protein (β A4), is the major proteinaceous constituent of Alzheimer's disease (AD) cortical senile plaques [1] and cerebrovascular amyloid [2]. It is derived from a large precursor protein: β A4 amyloid precursor protein (APP) [3–5]. Three major APP protein forms of 695 [3], 751 [4], and 770 amino acids [5], respectively, are derived from an alternatively spliced hn mRNA. APP is synthesized in the brain as well as in several other organs and tissues of healthy individuals (for reviews, see [6,7]). Until now, only cortical and hippocampal neurons, astrocytes, and endothelial cells have been reported to be cortical sites of APP synthesis [5,8–15].

Although numerous reactive microglia are consistently found in and around AD senile plaques [16–19] and although amyloid was found to be associated with them [17,18,20] nothing is known so far as to whether this cell population of the brain may synthesize APP and thus may contribute to β A4 deposits. The question remained open whether the material was synthesized by the cells themselves or whether it had been phagocytosed. Our intention was to obtain evidence whether or not human microglia might be able to express APP and how it may be regulated. We applied a previously described special cultivation system to obtain terminally

matured human macrophages from purified peripheral blood monocytes which feature many of the characteristics of human microglia [21,22]. The in-vitro matured monocyte-derived macrophages share morphological and immunological features with microglia: compared to monocytes, they show a typical macrophage-like ruffled cell membrane under the electron microscope [21], and express surface antigens such as MHC class II molecules, receptors for Fc, C3, transferrin, and the CD4 receptor [23,24]. In this report we show that monocyte-derived, in-vitro matured human macrophages constitutively express APP mRNA and synthesize APP protein.

2. MATERIALS AND METHODS

2.1. Human monocyte-macrophage cultures

Monocyte and monocyte-derived macrophage cultures were performed as previously described in detail [21,22]: monocytes were prepared from blood of healthy donors by centrifugation over Ficoll-Hypaque according to [25]. The mononuclear cell fraction was allowed to adhere to plastic dishes in supplemented RPMI 1640 medium (Seromed, Berlin, FRG) containing 10% human AB serum. Non-adherent cells (lymphocytes) were then removed resulting in highly monocyte-enriched cultures which were either used immediately for experiments or were further cultivated in order to obtain monocyte-derived macrophages. In the latter case, monocytes were incubated overnight and then removed from the dishes at 4°C by vigorous pipetting and placed into rectangular teflon bags (Biofolie 25; Heraeus, Hanau, FRG) in supplemented RPMI 1640 medium containing 10% human AB serum. After 8 days, the monocyte-derived macrophages exhibited features of typical tissue macrophages [23,24]. Cells were

Correspondence address: J. Bauer, Psychiatrische Universitätsklinik, Hauptstrasse 5, D-7800 Freiburg, Germany.

removed from the bags, sedimented on plastic dishes, and could be used for further experiments.

2.2. Human neuronal cell cultures

The SH-SY5Y neuroblastoma clone [26] was a gift from Dr J. Biedler, Memorial Sloan-Kettering Cancer Center (New York, N.Y.). The cells were grown in RPMI 1640 medium containing 1% FCS (Cibco, Karlsruhe, Germany). Murine nerve growth factor β (NGF β) (a generous gift from U. Otten, Basel, Switzerland), retinoic acid (Sigma, Delsenhofen, Germany), and dibutyl cAMP (db cAMP) (Sigma) were added to the medium for 5 days at a final concentration of 20 ng/ml, 10 μ M, and 0.5 mM, respectively. Addition of these components has been previously reported to result in a differentiated phenotype of neuronal cells [27].

2.3. Radiolabeling and immunoprecipitation

Radiolabeling of the cell cultures and immunoprecipitation was done as described earlier in detail [29]: cells were plated into 40 mm plastic dishes (10^6 cells/dish) in supplemented RPMI 1640 medium containing 1% FCS (neuronal cells) or 1% human AB serum (macrophages). Metabolic labeling was done by replacing media by methionine- and serum-free RPMI 1640 medium and by addition of [35 S]methionine (100 μ Ci/dish). Cells were allowed to incorporate the radioactive amino acid into newly synthesized proteins for 4 h except in the pulse-chase experiments, where cells were labeled with 200 μ Ci/dish for only 20 min followed by addition of an excess of unlabeled methionine (2 mM final concentration) in order to chase the radio-labeled methionine. For immunoprecipitation, media were separated from the cells. Cells were homogenized in 1 ml 25 mM Tris-HCl, pH 7.5; 20 mM NaCl; 1% sodium deoxycholate; 1% Triton X-100. Non-soluble material was removed by centrifugation at 12000 rpm for 5 minutes. Cell homogenates and media were diluted with 2 volumes of immunoprecipitation buffer (20 mM Tris-HCl, pH 7.6; 0.14 M NaCl; 5 mM EDTA; 1% Triton X-100). Total de-novo synthesized proteins were determined by TCA-precipitation of 20 μ l aliquots of cell homogenates and media according to [30]. Specific proteins were extracted from equivalent amounts of total TCA-precipitable radioactivity (usually 0.5×10^6 cpm from media, 2×10^6 cpm from cell homogenates). In the pulse-chase experiments, specific proteins were extracted from total medium and from one half of the cell homogenate. Prior to extraction with specific antibodies, unspecifically binding material was absorbed by a sham extraction with non-immune control serum. After addition of an excess of monospecific polyclonal anti-APP₆₉₅ antibody [38] (usually 10 μ l), the immune complexes were bound to Protein A Sepharose (Pharmacia, Freiburg, FRG), sedimented, and washed (2 times in immunoprecipitation buffer, 2 times in 50 mM sodium phosphate buffer, pH 7.5). The immune complexes were dissociated at 95°C for 5 min in 35 μ l of dissociation buffer (0.1 M Tris-HCl, pH 6.8; 5% 2-mercaptoethanol; 5% sodium dodecylsulfate; 10% glycerol), subjected to sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) according to [31], and fluorography according to [32]. The specific radioactive bands were cut out from the gels, solubilized with protosol/water (9:1) and counted in a liquid scintillation counter.

2.4. DNA constructs

Standard cloning techniques were applied [33]. A partial β A4-amyloid precursor protein/APP₇₇₀ cDNA of 2.7 kb was isolated from a human fetal brain lambda gt10 cDNA library using radioactively end-labeled oligonucleotide probes specific for the APP₇₇₀ cDNA as well as a *Bam*HI/*Xho*I restriction fragment (-47 to +1135, [3]), which was labeled by random priming [34,35]. A 1.7 kb *Eco*RI fragment of this cDNA, where the 5'-*Eco*RI restriction site derived from the adaptor (*Eco*RI-*Xho*I-*Sal*I) used during construction of the cDNA library, and the 3'-*Eco*RI site at position +2020 from the APP₇₇₀ cDNA, was subcloned into the *Eco*RI restriction site of the pUC19 polylinker, resulting in the recombinant plasmid p2.21. Digestion of plasmid p2.21 with *Xho*I resulted in a fragment with 815 bp of APP₇₇₀ cDNA. This fragment was cloned into the *Sal*I restriction

site of the M13mp18 polylinker, resulting in recombinant phage M8.11.

2.5. RNA extraction and S1 nuclease protection assay

Total RNA was extracted from cells according to [36]. The S1 nuclease protection assay was performed as described [37]. A uniformly labeled single-stranded DNA probe was synthesized by annealing 1 pmol of M13 phage specific oligonucleotide primer to 250 ng of single-stranded template DNA of M8.11. This primer was extended with 1 unit of Klenow polymerase (Boehringer, Mannheim, Germany) in the presence of 25 mM dATP, dGTP, dTTP, 2 mM dCTP, and 40 μ Ci of [α - 32 P]dCTP (300 Ci/mmol) for 15 min at 37°C. Extended products were digested with *Sae*I for 45 min. The labeled single-stranded DNA-probes were purified on a 5% denaturing polyacrylamide gel. Probes were visualized by autoradiography. Gel slices corresponding to the bands on the autoradiograph were cut out and electroeluted (Elutipur, Schleicher and Schüll). Excess probe M8.11 (50000 cpm) was hybridized overnight to 15 μ g of total RNA at 55°C (75% formamide, 0.4 M NaCl, 20 mM Tris-HCl, pH 7.4, and 1 mM EDTA). S1 nuclease digestion (1200 units/sample; Boehringer, Mannheim, Germany) was performed for 2 h at 37°C (0.3 M NaCl, 3 mM ZnSO₄, 60 mM NaAc, pH 4.5, 0.5 μ g denatured calf thymus DNA). The resulting products were once phenol- and once phenol/CHCl₃-extracted, ethanol-precipitated and resolved on a 5% denaturing sequencing gel. Autoradiography was done with Kodak X-OMAT AR films.

2.6. Immunocytochemical staining

Monocyte-derived macrophages were plated in 1640 medium on the manox plastic coverslips (Nunc, Ill. USA) and allowed to adhere. Cells were then washed with phosphate-buffered saline (PBS) and fixed with 4% formalin PBS. After incubation with a 1:10 dilution of the monospecific primary antibodies: monoclonal anti- β A4-amyloid precursor protein (Boehringer, Mannheim, Germany) or polyclonal anti α 2-macroglobulin [28], cells were treated with the Vectastain ABC-peroxidase detection system (Vector Lab., Burlingame, CA). Cells were mounted in glycerine (Merck, Darmstadt, Germany) and viewed with a Zeiss III RS microscope.

3. RESULTS

In-vitro matured macrophages were obtained by subjecting purified human peripheral blood monocytes to cultivation in hydrophobic teflon foils for 8 days. During this time, the cells increase in size (Fig. 1A) and develop features of tissue macrophages [23,24]. In freshly isolated blood monocytes synthesis of β A4-amyloid precursor protein (APP) was nearly undetectable (Fig. 1B, lane 1). However, after terminal maturation macrophages express high levels of APP both on the protein (Fig. 1B, lane 2) as well as at the mRNA level (Fig. 2). If RNA extracted from macrophages was analyzed by S1 nuclease protection analysis, APP mRNA coding for the 751 and for the 770 amino acid forms of the APP protein were found to be predominant, while only a faint signal was detected corresponding to the mRNA coding for the 695 amino acid form of the protein (Fig. 2).

The biosynthesis and secretion of APP was analyzed by a pulse-chase study. A comparison of synthesis and secretion in macrophages (Fig. 3, lanes 1-4) and human neuronal (SH-SY5Y neuroblastoma) cells (Fig. 3, lanes 5-8) revealed, that macrophages synthesize intracellular




Fig. 1. (A) Morphological characterization of in-vitro matured human macrophages compared to freshly isolated human blood monocytes. Pappenheim-stained freshly prepared human blood monocytes (left) and macrophages after in-vitro maturation (right) were viewed by oil immersion microscopy at the same magnification ($\times 2400$) for both pictures. (B) Secretion of β A4-amyloid precursor protein (APP) by freshly isolated human blood monocytes and by in-vitro matured macrophages. Adherence-purified human blood monocytes (lane 1) and in-vitro matured macrophages (lane 2) were metabolically radiolabeled, APP was immunoprecipitated from standardized amounts of secreted TCA-precipitable radioactivity (i.e. from standardized amounts of de-novo synthesized proteins) as described in Section 2, subjected to SDS-PAGE and autoradiography.

APP forms with an apparent molecular weight between 110 kDa and 130 kDa (Fig. 3, lane 1) corresponding to the *N*-glycosylated forms of APP₇₅₁ and APP₇₇₀ (about 110 kDa) and to the *N*- and *O*-glycosylated tyrosine sulfated mature membrane protein APP₇₅₁ and APP₇₇₀ (about 130 kDa) [38]. The same pattern was found in neuronal cells (Fig. 3, lane 5), however, these cells contained an additional APP form of approximately 98 kDa (lane 5, arrowhead). Most likely, this neuron-specific form represents *N*-glycosylated APP₆₉₅ ([38] see below). Secretory APP forms in the macrophage-conditioned medium had a molecular weight between 110 kDa and 125 kDa (Fig. 3, lane 4). Again, a neuron-specific additional APP₆₉₅ form gives rise to an additional band with a molecular weight of approximately 92 kDa (lane 8, arrowhead).

Molecular weight heterogeneity of APP has previous-

ly been shown to be due to the facts: first, that 3 differentially spliced major APP mRNA forms (coding for APP proteins with 695, 751, and 770 amino acids) are derived from hn mRNA [3-5]; second, that APP is subjected to posttranslational modifications including *N*- and *O*-glycosylation, sulfation, and proteolysis [38-40]. The secretory APP forms found in the conditioned medium are produced by a proteolytic cleavage C-terminal to residue 16 of the β A4 part of the mature APP transmembrane forms [39,40].

The presence of APP in macrophages was finally demonstrated by immunocytochemical staining. Figure 4A shows strong intracellular (mainly perinuclear) β APP immunoreactivity in macrophages. In addition, cells from the same preparation stain also for α -2-macroglobulin (Fig. 4B), a previously described marker of terminally matured macrophages [28].




Fig. 2. Detection of APP mRNA in freshly isolated human blood monocytes and in-vitro matured macrophages by S1 nuclease protection assay. 15 μ g of total RNA from freshly isolated human blood monocytes (lane 1) and from in-vitro matured macrophages (lane 2) were hybridized to an excess of APP probe M8.11 and digested with S1 nuclease. The resulting protected fragments were subjected to a 5% denaturing polyacrylamide gel electrophoresis. The protected fragments of 815 bases for the β APP₇₇₀ mRNA, of 714 bases for the β APP₇₅₁ mRNA and of 546 bases for the β APP₆₉₅ mRNA are indicated.

4. DISCUSSION

As the resident macrophages of the brain, microglia are linked to the mononuclear phagocyte system (for recent reviews see [41-43]). Here we describe that cells of the mononuclear phagocyte system, linking bone marrow precursors, blood monocytes, and the different tissue macrophages, strongly express APP upon terminal maturation from monocytes to macrophages. Treatment of the macrophages with endotoxin (a classical stimulans) or glucocorticoids did not affect APP synthesis (not shown). Like in other non-neuronal cells [44-46], APP₇₅₁ and APP₇₇₀ are the major APP forms in macrophages. Expression of APP₆₉₅ is nearly exclusively restricted to neuronal cells where it is expressed in a [751+770]:[695] ratio of about 1:1 [44-46]. Several reports describe an increased ratio of [751+770]:[695] APP mRNA in AD brain [47-49]. This finding may be explained by an age-dependent alteration [50] and/or by gliosis which is commonly observed in AD [48]. It remains to be elucidated whether the changed ratio in APP expression is an early or late event of Alzheimer's disease pathophysiology.

In AD brain, senile plaques are consistently found to




Fig. 3. Comparison of the APP forms synthesized and secreted by in-vitro matured human macrophages and by human neuronal (neuroblastoma) cells. In-vitro matured human macrophages (lanes 1-4) and human SH-SY5Y neuroblastoma cells were pulse-labeled with 200 μ Ci of [³⁵S]methionine for 20 min. Then the cultures were harvested either immediately (lanes 1,3,5,7) or cultivated for 4 more hours in the presence of an excess of unlabeled methionine (2 mM final concentration) in order to chase the incorporated radioactive methionine (lanes 2,4,6,8). Cultures were harvested by separating culture media from cells. APP was immunoprecipitated from half volume of cell homogenates (lanes 1,2,5,6) and from total media (lanes 3,4,7,8), subjected to SDS-PAGE and autoradiographed. Unspecifically binding material was preabsorbed from cell homogenates (P_c) and media (P_m) using non-immune control serum. Arrowheads point to an APP form produced in neuronal cells only.

contain and to be surrounded by reactive microglia [18-20]. Resident microglia are derived from immigrating monocytes which then undergo terminal maturation into resident microglia [18-20]. This immigration occurs mainly in the perinatal period, but a low degree of immigration has been assumed to occur throughout life [18-20]. Injury or infection in the central nervous system give rise to the appearance of both reactive microglia (i.e. activated resident microglia) and activated macrophages (i.e. mononuclear phagocytes recruited from the circulation) [41-43]. The local environment may influence the behaviour of resident macrophages in the different tissues. Therefore, data obtained with in-vitro matured macrophages must be interpreted with caution. It is impossible to determine to which of the microglial cell types (resident microglia, activated microglia, or activated macrophages) our in-vitro matured macrophages are best correlated. However,




Fig. 4. Immunocytochemical staining for APP of in-vitro-matured macrophages with a monoclonal antibody directed against β A4-amyloid precursor protein (A) and a polyclonal antibody directed against alpha 2-macroglobulin (B). Control stains with rabbit non-immune serum were completely without stain (not shown). Magnification $\times 375$.

since APP expression was not altered upon stimulation of our cells with the classical activator endotoxin, the state of activation seems to be of minor significance for APP expression. Instead, APP expression seems to critically depend upon the terminal step of mononuclear phagocyte maturation. We assume that APP expression of in-vitro matured macrophages may serve as evidence for synthesis in microglial cells. Very recently, this assumption was supported by immunocytochemical detection of APP in primary cultures of human microglia (P. Gebicke-Haerter, J. Bauer, B. Volk, in preparation).

The physiological functions of APP are still unclear. The secretory (N-terminal) part of APP₇₅₁ (which, like APP₇₇₀, bears a Kunitz-type protease inhibitor domain) has been found to be identical to protease nexin II [51, 52]. Functions of this molecule include inhibition of coagulation factor XI a, plasmin, trypsin, chymotrypsin, and nerve growth factor gamma (which is involved in NGF processing) [5, 51–55]. In addition, binding to epidermal growth factor binding protein and to transforming growth factor beta has been observed [51, 52, 54, 56]. Since neurite outgrowth depends on a precarious balance between proteases and their inhibitors [57], it appears conceivable that the protease inhibitors APP₇₅₁ and APP₇₇₀ may interfere with neuronal plasticity. With respect to the β A4 peptide, its effects on undifferentiated neurons seem to be beneficial and to support neuronal differentiation [58, 59]. In contrast, β A4 was found to exert neurotoxic effects on differentiated neurons [59–61].

The mechanisms by which APP contributes to the pathology of Alzheimer's disease are not yet fully understood. A detailed analysis of APP biosynthesis in cultured cells revealed that APP, after its insertion into the cell membrane as a transmembrane protein [3, 38, 62], is cleaved *inside* the β A4-sequence of the mature APP

protein by a still unknown secretase resulting in the secretory release of the large N-terminal portion of APP [39, 40]. Therefore, it can be concluded that the formation of the β A4 peptide is prevented under normal physiological conditions. Vice versa, it appears conceivable that a protease inhibitor may inhibit the APP secretase in Alzheimer's disease (AD) and may thus preserve the β A4 peptide from being cleaved. Pathologic APP breakdown could then give rise to β A4 which due to its tendency to aggregate may contribute to plaque formation. In fact, we recently found that human neuronal cells synthesize and secrete the most potent of the known endogenous protease inhibitors, alpha2-macroglobulin (a2M), upon stimulation with the inflammatory cytokine Interleukin-6 (IL-6) [63]. a2M was found to inhibit APP secretion [63] and both a2M and IL-6 could be detected in AD senile plaques (B. Volk and J. Bauer, submitted).

Once normal APP processing is disturbed, APP from any source inside the brain might contribute to β A4 and subsequent plaque formation. Our data show that tissue macrophages contribute to APP synthesis and thus provide evidence that APP may be synthesized also by brain microglia. However, further studies have to be carried out to elucidate how exactly microglial cells may contribute to the pathophysiology of Alzheimer's disease.

Acknowledgements: This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG) (J.B. by SFB 154; K.B. by SFB 317) and from the Fritz Thyssen Stiftung (J.B.). G.K. is a fellow of the Boehringer Ingelheim Fond.

REFERENCES

- [1] Masters, C.L., Simms, G., Weinmann, N.A., Multhaup, G., McDonald, B.L. and Beyreuther, K. (1985) *Proc. Natl. Acad. Sci. USA* 82, 4245–4249.

- [2] Glenner, G.G. and Wong, C.W. (1984) *Biochem. Biophys. Res. Commun.* 120, 885-890.
- [3] Kang, J., Lemaire, H.G., Unterbeck, A., Salbaum, J.M., Masters, C.L., Grzeschick, K.H., Multhaup, G., Beyreuther, K. and Müller-Hill, B. (1987) *Nature* 325, 733-736.
- [4] Ponte, P., Gonzalez-DeWhitt, P., Schilling, J., Miller, J., Hsu, D., Greenberg, B., Davis, K., Wallace, W., Lieberburg, I., Fuller, F. and Cordell, B. (1988) *Nature* 331, 525-527.
- [5] Kitaguchi, N., Takahashi, Y., Tokushima, Y., Shiliri, S. and Ito, H. (1988) *Nature* 331, 530-532.
- [6] Müller-Hill, B. and Beyreuther, K. (1989) *Annu. Rev. Biochem.* 58, 287-307.
- [7] Selkoe, D.J. (1990) *Science* 248, 1058-1060.
- [8] Bahmanyar, S., Higgins, G.A., Goldgaber, D., Lewis, D.A., Morrison, J.H., Wilson, M.C., Shankar, S.K. and Gajdusek, D.C. (1987) *Science* 237, 77-80.
- [9] Goedert, M. (1987) *EMBO J.* 6, 3627-3632.
- [10] Shivers, B.D., Hilbich, K., Multhaup, G., Salbaum, M., Beyreuther, K. and Seeburg, P.H. (1988) *EMBO J.* 7, 1365-1370.
- [11] Higgins, G.A., Lewis, D.A., Bahmanyar, S., Goldgaber, D., Gajdusek, D.C., Young, W.G., Morrison, J.H. and Wilson, M.C. (1988) *Proc. Natl. Acad. Sci. USA* 85, 1297-1301.
- [12] Tate-Ostrow, B., Majocha, R.E. and Marotta, C.A. (1989) *Proc. Natl. Acad. Sci. USA* 86, 745-749.
- [13] Grundke-Iqbal, I., Iqbal, K., George, L., Tung, Y.C., Kim, K.S. and Wisniewski, H.M. (1989) *Proc. Natl. Acad. Sci. USA* 86, 2853-2857.
- [14] Benowitz, L.L., Rodriguez, W., Paskevich, P., Mufson, E.J., Schenk, D. and Neve, R.L. (1989) *Exp. Neurol.* 106, 237-250.
- [15] Chou, W.G., Zain, S.B., Rehman, S., Tate-Ostrow, B., Majocha, R.E., Benes, F.M. and Marotta, C.A. (1990) *J. Psychiatr. Res.* (1990) 24, 37-50.
- [16] Wisniewski, H.M. and Terry, R.D. (1973) in: *Progress in Neuro-pathology* (Zimmermann, H.M., ed.) Grune and Stratton, New York, pp. 1-26.
- [17] Kozlowski, P., Wisniewski, H.M., Moretz, R.C. and Lossinsky, A.S. (1981) *Ann. Neurol.* 10, 517-523.
- [18] Itagaki, S., McGeer, P.L., Akiyama, H., Zhu, S. and Selkoe, D. (1989) *J. Neuroimmunol.* 24, 173-182.
- [19] Styren, S.D., Civin, W.H. and Rogers, J. (1990) *Exp. Neurol.* 110, 93-104.
- [20] Perlmutter, L.S., Barron, E. and Chiang Chui, H. (1990) *Neurosci. Lett.* 119, 32-36.
- [21] Bauer, J., Ganter, U., Geiger, T., Jacobshagen, U., Hirano, T., Matsuda, T., Kishimoto, T., Andus, T., Acs, G., Gerok, W. and Ciliberto, G. (1988) *Blood* 72, 1134-1140.
- [22] Bauer, J., Bauer, T.M., Kalb, T., Taga, T., Lengyel, G., Hirano, T., Kishimoto, T., Acs, G., Mayer, L. and Gerok, W. (1989) *J. Exp. Med.* 170, 1537-1549.
- [23] Andreessen, R., Gadd, S., Brugger, W., Löhr, G.W. and Atkins, R.C. (1988) *Immunobiology* 177, 186-198.
- [24] Andreessen, R., Brugger, W., Scheibenbogen, C., Kreutz, M., Leser, H.G., Rehm, A. and Löhr, G.W. (1990) *J. Leukoc. Biol.* 47, 490-497.
- [25] Boyum, A. (1976) *Scand. J. Immunol.* 5, 9-15.
- [26] Biedler, J.L., Roffler-Tarlow, S., Schachner, M. and Freedman, L.S. (1987) *Cancer Res.* 38, 3751-3757.
- [27] Bottenstein, J.E. (1981) in: *Functionally differentiated cell lines*, Alan R. Liss, New York, pp. 155-184.
- [28] Ganter, U., Bauer, J., Schulz-Huotari, C., Gebicke-Haerter, P.J., Beeser, H. and Gerok, W. (1987) *Eur. J. Biochem.* 169, 13-20.
- [29] Bauer, J., Kurdowska, A., Tran-Thie, T.A., Budek, W., Koj, A., Decker, K. and Heinrich, P.C. (1985) *Eur. J. Biochem.* 146, 347-352.
- [30] Mans, R.J. and Novelli, G.D. (1961) *Arch. Biochem. Biophys.* 94, p. 48.
- [31] King, J. and Lämmli, U. (1971) *J. Mol. Biol.* 62, 465-477.
- [32] Bonner, J. and Laskey, R.A. (1974) *Eur. J. Biochem.* 46, 83-88.
- [33] Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, 1989.
- [34] Feinberg, A.P. and Vogelstein, B. (1983) *Anal. Biochem.* 132, 6-13.
- [35] Meinkoth, J. and Wahl, G. (1984) *Anal. Biochem.* 138, 267-284.
- [36] Chomczynski, P. and Sacchi, N. (1987) *Anal. Biochem.* 162, 156-160.
- [37] Ruppert, C., Goldowitz, D. and Wille, W. (1986) *EMBO J.* 5, 1897-1901.
- [38] Weidemann, A., König, G., Bunke, D., Fischer, P., Salbaum, J.M., Masters, C.L. and Beyreuther, K. (1989) *Cell* 57, 115-126.
- [39] Sisodia, S.S., Koo, E.H., Beyreuther, K., Unterbeck, A. and Price, D.L. (1990) *Science* 248, 492-495.
- [40] Esch, F.S., Keim, P.S., Beattie, E.C., Blacher, R.W., Culwell, A.R., Oltersdorf, T., McClure, D. and Ward, P.J. (1990) *Science* 248, 1122-1124.
- [41] Perry, V.H. and Gordon, S. (1988) *Trends Neurol. Sci.* 6, 273-277.
- [42] Streit, W.J., Grachner, M.B. and Kreutzberg, G.W. (1988) *Glia* 1, 301-307.
- [43] Jordan, F.L. and Thomas, W.E. (1988) *Brain Res. Rev.* 13, 165-178.
- [44] Tanzi, R.E., McClatchey, A.I., Lamperti, E.D., Villa-Komaroff, L., Gusella, J.F. and Neve, R.L. (1988) *Nature* 331, 528-530.
- [45] Koo, E.H., Sisodia, S.S., Archer, D.R., Martin, L.J., Weidemann, A., Beyreuther, K., Fischer, P., Master, C.L. and Price, D.L. (1990) *Proc. Natl. Acad. Sci. USA* 87, 1561-1565.
- [46] Kang, J. and Müller-Hill, B. (1990) *Biochem. Biophys. Res. Commun.* 166, 1192-1200.
- [47] Johnson, S.A., McNeill, T., Cordell, B. and Finch, C.E. (1990) *Science* 248, 854-857.
- [48] Golde, T.E., Estus, S., Usiak, M., Younkin, L.H. and Younkin, S.G. (1990) *Neuron* 4, 153-167.
- [49] Koo, E.H., Sisodia, S.S., Cork, L.C., Unterbeck, A., Baynay, R.M. and Price, D.L. (1990) *Neuron* 2, 97-104.
- [50] König, G., Salbaum, J.M., Wiestler, O., Lang, W., Schmitt, H.P., Masters, C.L. and Beyreuther, K. (1991) *Mol. Brain Res.* (in press).
- [51] Oltersdorf, T., Fritz, L.C., Schenk, D.B., Lieberburg, I., Johnson-Wood, K.L., Beattie, E.C., Ward, P.J., Blacher, R.W., Dovey, H.F. and Sinha, S. (1989) *Nature* 341, 144-147.
- [52] Van Nostrand, W.E., Wagner, S.L., Farrow, J.S. and Cunningham, D.D. (1990) *J. Biol. Chem.* 265, 9591-9594.
- [53] Kido, H., Fukutomi, A., Schilling, J., Wang, Y., Cordell, B. and Katanuma, N. (1990) *Biochem. Biophys. Res. Commun.* 167, 716-721.
- [54] Sinha, S., Dovey, H.F., Seubert, P., Ward, P.J., Blacher, R.W., Blaber, M., Bradshaw, R.A., Arici, M., Mobley, W.C. and Lieberburg, I. (1990) *J. Biol. Chem.* 265, 8983-8985.
- [55] Castro, M., Marks, C.B., Nilsson, B. and Anderson, S. (1990) *FEBS Lett.* 267, 207-212.
- [56] Bodmer, S., Podlisny, M.B., Selkoe, D.J., Heid, I. and Fontana, A. (1990) *Biochem. Biophys. Res. Commun.* 171, 890-897.
- [57] Monard, D. (1988) *Trends Neurol. Sci.* 11, 541-544.
- [58] Whitson, J.S., Selkoe, D.J. and Cotman, C.W. (1989) *Science* 243, 1488-1490.
- [59] Yankner, B.A., Duffy, L.K. and Kirschner, D.A. (1990) *Science* 250, 279-282.
- [60] Yankner, B.A., Dawes, L.R., Fisher, S., Villa-Komaroff, L.V., Oster-Granite, M.L. and Neve, R.L. (1989) *Science* 245, 417-420.
- [61] Yankner, B.A., Caceres, A. and Duffy, L.K. (1990) *Proc. Natl. Acad. Sci. USA* 87, 9020-9023.
- [62] Dykes, T., Weidemann, A., Multhaup, G., Salbaum, J.M., Lemaire, H.G., Kang, J., Müller-Hill, B., Masters, C.L. and Beyreuther, K. (1988) *EMBO J.* 7, 949-957.
- [63] Ganter, U., Strauss, S., Jonas, U., Weidemann, A., Beyreuther, K., Volk, B., Berger, M. and Bauer, J. (1991) *FEBS Lett.* (in press).